Neurocrine Biosciences, Inc. (NBIX) News
Track canonical SquawkNews coverage tagged to NBIX, Neurocrine Biosciences, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 20 indexed stories across 13 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Eiry W. Roberts named Chief Medical Officer at Neurocrine; Sanjay Keswani to depart
Neurocrine appointed Eiry W. Roberts as Chief Medical Officer effective September 28, 2026, succeeding Sanjay Keswani, whose service terminated September 25, 2026.Original SEC Filing: NEUROCRINE BIOSCIENCES INC [ NBIX ]
REGULATION | Sep 28, 2026, 08:27 PM UTC
L
NBIX: AI, China partnerships, and a strong pipeline drive growth amid evolving policy and pricing
China-originated innovation and AI adoption are accelerating development and operational efficiency. INGREZZA and CRENESSITY drive robust growth, while policy changes and new pipeline assets shape future revenue. AI and
GEOPOLITICS | Sep 15, 2026, 04:42 PM UTC
L
NBIX: Biotech growth is driven by innovation, AI adoption, and a diversified, resilient product pipeline
China's innovation is reshaping biotech competition, prompting a focus on speed and selectivity in R&D. AI adoption is driving productivity, while Medicare policy changes will impact pricing in 2029. Growth is supported
GEOPOLITICS | Sep 15, 2026, 04:00 PM UTC
L
NBIX: Multi-product growth, robust pipeline, and strategic adaptation position for long-term success
Expanded from a single to multi-product portfolio with strong sales and a robust pipeline. INGREZZA drives growth with further upside from sales force expansion, while upcoming regulatory changes will impact pricing but
EQUITY | Sep 10, 2026, 02:09 PM UTC
L
NBIX: Multi-product growth, robust pipeline, and strategic pricing drive sustained momentum
The company has evolved into a multi-product, high-growth enterprise with a robust pipeline and strong financials. INGREZZA continues to drive growth, supported by sales force expansion and favorable market dynamics, whi
EQUITY | Sep 10, 2026, 01:42 PM UTC
M
NBIX quarterly revenue hits $1 billion on Ingrezza, CRENESSITY growth
Quarterly revenue reached $1 billion, led by strong growth in Ingrezza, CRENESSITY, and VYKAT XR. Ingrezza remains in double-digit growth; CRENESSITY exceeded expectations with robust adoption and persistency.
EQUITY | Sep 09, 2026, 06:39 PM UTC
M
NBIX quarterly revenue hits $1 billion on Ingrezza, CRENESSITY strength
NBIX reported quarterly revenue of $1 billion, supported by growth in Ingrezza, CRENESSITY and VYKAT XR. The company cited outperforming Ingrezza and CRENESSITY expectations plus pipeline catalysts and commercial initiat
EQUITY | Sep 09, 2026, 06:07 PM UTC
L
Ten healthcare stocks with A-rated valuations and strong revenue growth
Healthcare stocks remain a focal point for investors as pharmaceutical innovation, biotechnology advancements, and managed care expansion continue to drive growth across the sector.While many healthcare companies trade a
EQUITY | Sep 09, 2026, 03:01 PM UTC
L
RBC Capital keeps price target at $198 for Neurocrine
RBC Capital maintained its price target of $198.00 per share on Neurocrine (NBIX).
EQUITY | Sep 08, 2026, 03:07 PM UTC
L
Citigroup raises Neurocrine price target to $253 from $249
Citigroup raised its Neurocrine price target to $253.00 per share from $249.00.
EQUITY | Sep 03, 2026, 04:35 PM UTC
L
NBIX - Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
NBIX - Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
EQUITY | Sep 02, 2026, 08:01 PM UTC
M
NBIX gets FDA IND acceptance for NBI-1117567 Phase 2 Alzheimer’s cognition
Neurocrine Biosciences, Nxera Pharma’s partner, received FDA IND acceptance for a Phase 2 study of NBI-1117567 targeting Alzheimer’s cognition.
EQUITY | Aug 26, 2026, 07:37 AM UTC
M
NBIX: Neurocrine Biosciences Publishes KINECT-PRO Findings
Neurocrine Biosciences publishes KINECT-PRO findings on INGREZZA
EQUITY | Aug 12, 2026, 12:31 PM UTC
H
NBIX Drug Vykat XR Linked to Deaths
NBIX's Vykat XR is linked to deaths and severe side effects, experts warn
EQUITY | Aug 12, 2026, 09:35 AM UTC
H
NBIX Raised to $119.98 at RBC
RBC raises NBIX price target
EQUITY | Jul 31, 2026, 12:12 PM UTC
H
NBIX price target raised to $204
NBIX price target raised to $204 from $200
EQUITY | Jul 31, 2026, 09:45 AM UTC
L
NBIX NBIX - Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
NBIX NBIX - Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
EQUITY | Jul 30, 2026, 08:01 PM UTC
L
NBIX Neurocrine Biosciences RESULTS: Q2, Q2 ADJ EPS $2.85 vs. EST $1.34, Q2 EPS $1.39, Q2 ADJ Net Income $297M vs. EST $141.4M, Q2 Net Incom
NBIX Neurocrine Biosciences RESULTS: Q2, Q2 ADJ EPS $2.85 vs. EST $1.34, Q2 EPS $1.39, Q2 ADJ Net Income $297M vs. EST $141.4M, Q2 Net Income $144M
EARNINGS | Jul 30, 2026, 08:01 PM UTC
L
Neurocrine Biosciences Insider Sold Shares Worth $2,603,112, According to a Recent SEC Filing
() -- Ingrid Delaet, Chief Regulatory Officer, on July 07, 2026, sold 14,571 shares in Neurocrine Biosciences (NBIX) for $2,603,112. Following the Form 4 filing with the SEC, Delaet has control over a total of 16,225 com
REGULATION | Jul 10, 2026, 08:02 AM UTC
L
Neurocrine Biosciences Initiates Phase 2 Clinical Study To Assess Crinecerfont In Children Aged 3 Months To Under 4 Years With Classic Conge
Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 years with classic cong
EQUITY | Jul 01, 2026, 08:08 PM UTC